Bone News and Research

RSS

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.

5 Nov 2009

SpineSmith Partners signs product development agreement with GenOsteo

SpineSmith Partners has signed an initial agreement with GenOsteo, Inc. to co-develop a unique scaffold that mimics the structure of natural cancellous bone.

5 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

MiddleBrook Pharmaceuticals, Inc. today announced its financial and operational results for the quarter ended Sept. 30, 2009.

5 Nov 2009

Imagenetix awarded U.S. patent for its 1-TDC drug candidate to treat periodontal disease

Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.

5 Nov 2009

New Merck set to begin global health care operations

Merck & Co., Inc. today outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation announced yesterday. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.

5 Nov 2009

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.

4 Nov 2009

Shire receives FDA Priority Review for velaglucerase alfa NDA

Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.

4 Nov 2009

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

Leprosy: Man's persistent companion

For thousands of years an undesirable and persistent companion has been travelling with man wherever he goes. Mycobacterium leprae, the bacterium that causes leprosy, has only one known natural host - mankind.

4 Nov 2009

Medical imaging cuts will cost lives

Medical imaging cuts contained in the 2010 Medicare Physician Fee Schedule will restrict life-saving imaging care to large hospitals, produce longer commutes and wait times to receive care, and cause life threatening delays in diagnosis and treatment of cancer and other serious illnesses.

4 Nov 2009

Shorter toes in modern humans could be an evolutionary adaptation for efficient distance running

Longer toes and a unique ankle structure provide sprinters with the burst of acceleration that separates them from other runners, according to biomechanists.

4 Nov 2009

Lap band surgery effective for morbidly obese adolescents, improves glucose metabolism

Washington, DC-A surgeon now at Children's National Medical Center and his colleagues from New York University have found laparoscopic adjustable gastric banding (Lap band) to improve the health of morbidly obese adolescents.

4 Nov 2009

Findings may lead to new drug therapies to reduce breast cancer metastasis

Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer.

4 Nov 2009

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP.

4 Nov 2009

Breastfeeding: ADA position paper details health benefits for both infants and mothers

The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.

4 Nov 2009

Stereotactic radiosurgery effectively controls pain in patients with cancer

Stereotactic radiosurgery (SRS), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, effectively controls pain in patients with cancer that has spread to the spine, according to researchers from UPCI.

4 Nov 2009

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.

3 Nov 2009

$3.9 million Challenge grant for Thomas Jefferson researchers

Four researchers from Thomas Jefferson University have received $3.9 million in Challenge grant funds as part of the American Recovery and Reinvestment Act.

3 Nov 2009

Bone News and Research

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

SpineSmith Partners signs product development agreement with GenOsteo

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

Imagenetix awarded U.S. patent for its 1-TDC drug candidate to treat periodontal disease

New Merck set to begin global health care operations

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Shire receives FDA Priority Review for velaglucerase alfa NDA

Safeguard Scientifics reports financial results for the third quarter of 2009

Leprosy: Man's persistent companion

Medical imaging cuts will cost lives

Shorter toes in modern humans could be an evolutionary adaptation for efficient distance running

Lap band surgery effective for morbidly obese adolescents, improves glucose metabolism

Findings may lead to new drug therapies to reduce breast cancer metastasis

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Breastfeeding: ADA position paper details health benefits for both infants and mothers

Stereotactic radiosurgery effectively controls pain in patients with cancer

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

$3.9 million Challenge grant for Thomas Jefferson researchers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News